PrimaryCareNOW: A Pri-Med Virtual Conference | Pri-Med

Join your clinician colleagues and expert faculty for PrimaryCareNOW: A Pri-Med Virtual Conference on Thursday–Friday, October 7–8. This free remote learning experience includes:

  • A carefully curated CME/CE curriculum, moderated by Pamela Kushner, MD, FAAFP, and Charles Vega, MD, FAAFP
  • Interactive, live Q&A with distinguished faculty, including experts from top healthcare institutions across the country
  • The opportunity to earn up to 12.50 AMA PRA Category 1 Credits™ and 12.50 ABIM Medical Knowledge MOC Points, or 12.50 AANP contact hours of continuing education, including 1.33 hours of pharmacology
  • Access to on-demand CME/CE courses

Your free registration includes the full conference, but you're welcome to join the sessions that best fit your schedule. Agenda and details are subject to change.

To register for this virtual conference, you will be asked to sign in to your Pri-Med account. If you do not have an account, you can create your free account now, which takes less than two minutes.


Agenda

  CME/CE Accredited Session

Non-CME/CE Session
Sponsored by Industry

Click For Session Details
Session Times Listed in ET

8–11:30am ET    CME/CE Accredited Session

Pain

Strategies for Effective Pain Management in Clinical Practice 

Charles E. Argoff, MD, FABPM | Oscar A. de Leon-Casasola, MD | Katherine E. Galluzzi, DO, CMD, FACOFP

 

The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain vs the crisis of prescription opioid abuse. Pri-Med’s Strategies for Effective Pain Management in Clinical Practice curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including nonopioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse in order to optimally manage patients’ pain and medication use.

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).

Charles E. Argoff, MD, FABPM

Professor of Neurology, Albany Medical College, Director, Comprehensive Pain Center, Albany Medical Center, Albany, NY

Oscar A. de Leon-Casasola, MD

Professor of Anesthesiology and Medicine, Senior Vice-Chair, The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, Chief, Pain Medicine and Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY

Katherine E. Galluzzi, DO, CMD, FACOFP

FACOFP, Professor and Chair, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, PAs

Supported by Opioid Analgesic REMS Program Companies

11:40am–12:25pm ET    Non-CME Industry Theater

Gastroenterology

 

Discuss the diagnosis of Exocrine Pancreatic Insufficiency (EPI) and the treatment with CREON.

Sponsored by AbbVie

11:40am–12:25pm ET    Non-CME Industry Theater

Pulmonology

 

  • Review updated treatment paradigms for severe asthma.
  • Evaluate the benefit-risk of oral corticosteroid use in severe uncontrolled asthma and the need for OCS stewardship.
  • Discuss the role of biologics as a preferred treatment option for severe asthma management.

Sponsored by AstraZeneca

11:40am–12:25pm ET    Non-CME Industry Theater

Pediatrics

Barbara Burton, MD

 

This educational program will provide a practical overview pertaining to the significant role of primary care providers in pediatric developmental surveillance and screening. The importance of early developmental delay identification, with attention to neuromotor milestones, will be reviewed, including implications for rarer pediatric diseases, such as lysosomal storage disorders.

Default Biography Avatar

Barbara Burton, MD

Northwestern University Feinberg School of Medicine, Attending Physician and Clinical Practice Director, Division of Genetics, Metabolism, and Birth Defects, Ann and Robert H. Lurie Children’s Hospital, Chicago, Illinois

Sponsored by Takeda

12:35–1:35pm ET    CME/CE Accredited Session

Endocrinology

 

More than half of patients with type 2 diabetes are obese. Modest and sustained weight loss has been shown to improve glycemic control and reduce the need for glucose-lowering medications in patients with type 2 diabetes who are obese. Despite the proven benefits of weight loss, most patients remain on therapeutic regimens that focus solely on lowering A1c. This program will provide evidence-based strategies for managing both glycemic and metabolic outcomes and explore the role of the incretin hormones GLP-1 and GIP in the treatment of type 2 diabetes and its metabolic comorbidities.  

Silvio E. Inzucchi, MD

Professor of Medicine, Clinical Chief, Endocrinology, Medical Director, Yale Diabetes Center, Yale School of Medicine, Yale-New Haven Hospital, New Haven, CT

Anne Peters, MD

Professor of Clinical Medicine, Keck School of Medicine of USC, Los Angeles, CA

Supported by Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

1:45–2:45pm ET    CME/CE Accredited Session

Cardiology

Cardiology Essentials for the PCP 

Ty J. Gluckman, MD, FACC, FAHA

 

Session Overview to Come 

Ty J. Gluckman, MD, FACC, FAHA

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS), Providence Heart Institute, Providence St. Joseph Health, Portland, OR

2:55–3:40pm ET    Non-CME Industry Theater

2:55–3:40pm ET    Non-CME Industry Theater

Endocrinology

Jeff Unger, MD, FAAFP, FACE

 

Review the pathophysiology of T2D and the recommendations from relevant associations on the oral treatment options that should be used after metformin in the T2D treatment plan. Discuss head-to-head data for a once-daily treatment option from pivotal glycemic control trials and safety data from a cardiovascular outcomes trial, followed by dosing and administration information.

Jeff Unger, MD, FAAFP, FACE

Diplomate, American Board of Family Practice, Assistant Clinical Professor of Family Medicine, UC Riverside School of Medicine, Riverside, California, Director, Unger Concierge Primary Care Medical Group, Rancho Cucamonga, California

Sponsored by Novo Nordisk Inc.

3:50–4:50pm ET    CME/CE Accredited Session

Neurology

 

One in fifty people in the U.S. has an unruptured brain aneurysm, and one ruptures every 18 minutes. Despite low frequency, brain aneurysms are high in mortality, because the lack of a timely diagnosis often leads to death. Complicating matters more, many of the symptoms are associated with other less dangerous conditions, such as influenza or stress. This session will describe the importance of early detection, since brain aneurysms are treatable via proper identification, and will highlight risk factors and populations who are most vulnerable. Faculty will also review treatment options for clinicians to recognize or use in practice. 

Christopher S. Ogilvy, MD

Director, Endovascular and Operative Neurovascular Surgery, BIDMC Brain Aneurysm Institute, Professor of Neurosurgery, Harvard Medical School, Boston, MA

5–5:45pm ET    Non-CME Industry Theater

8–9am ET    CME/CE Accredited Session

Hot Topics

 

What do primary care providers need to know about HCV and glaucoma? Join expert faculty as they review important questions they get asked about these topics!

Sammy Saab, MD, MPH, AGAF

Speaker’s Bureau for Gilead, , Salix, Abbvie, Advisory Board for Gilead

9:10–10:10am ET    CME/CE Accredited Session

Women's Health

 

Session Overview to Come

10:20–11:05am ET    Non-CME Industry Theater

Pulmonology

 

Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

10:20–11:05am ET    Non-CME Industry Theater

Gastroenterology

 

*This is a hypothetical case and not an actual patient    

Uncover the cause of the patient's symptoms in this virtual case study and consider if this could apply to any patients you manage.

Sponsored by Takeda Pharmaceuticals U.S.A., Inc.

10:20–11:05am ET    Non-CME Industry Theater

Endocrinology

Surendra Sivarajah

 

  • Recognize the health burden and prevalence of CKD.
  • Understand CKD risk factors and the progressive nature of renal function decline.
  • Identify the risk of CKD in patients with T2D.
  • Review screening and monitoring recommendations in CKD.
  • Highlight current approaches to the management of CKD.

Surendra Sivarajah

Field Physician, Biopharmaceuticals, US Medical | CVMD

Sponsored by AstraZeneca

11:15am–12:15pm ET    CME/CE Accredited Session

Infectious Disease

COVID Panel 

Kalpana Gupta, MD, MPH

 

Session Overview to Come

Kalpana Gupta, MD, MPH

Kalpana Gupta, MD, MPH

12:25–1:25pm ET    CME/CE Accredited Session

Gastroenterology

 

This activity will provide an evidence-based approach to the diagnosis and management of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), with minimal diagnostic testing. The faculty will describe evidence-based treatment guidelines and discuss the efficacy of over-the-counter and prescription agents prioritized within the guidelines. This will help you navigate the progress from patient education to diet plus over-the-counter agents to prescription agents.

Philip Schoenfeld, MD, MSEd, MSc

Chief (Emeritus) - Gastroenterology Section, John D. Dingell VA Medical Center, Detroit, MI

Supported by Supported by an educational grant from AbbVie Inc. and Takeda Pharmaceuticals U.S.A., Inc..

1:35–2:20pm ET    Non-CME Industry Theater

Pediatrics

 

Sponsored by Sanofi Genzyme

1:35–2:20pm ET    Non-CME Industry Theater

Neurology

 

Sponsored by AbbVie

2:30–3:30pm ET    CME/CE Accredited Session

3:40–4:40pm ET    CME/CE Accredited Session

Hot Topics

Challenging Cases in Primary Care 

Charles Vega, MD, FAAFP

 

In this session, the speaker will discuss some challenging diagnostic cases that primary care practitioners may face in their practice. These cases will feature interpretation of laboratory and imaging studies as well as encounters with rare diseases and conditions. You will learn which aspects of the history and physical exam are most useful to establish certain diagnoses, increase your awareness of certain uncommon but “can’t miss” diagnoses, and become familiar with clinical decision aids that improve diagnostic accuracy for certain common diagnoses.

Charles Vega, MD, FAAFP

Health Sciences Clinical Professor, UC Irvine Department of Family Medicine, Assistant Dean for Culture and Community Education, Executive Director, UC Irvine Program in Medical Education for the Latino Community, UC Irvine School of Medicine, Irvine, CA

4:50–5:35pm ET    Non-CME Industry Theater

Cardiology

 

  • Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
  • Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population.
  • Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial.
 

Ted Okerson, MD, FACP, FACE

Dr. Okerson currently serves as a Sr. Field Physician within the Biopharmaceuticals US Medical Team for AstraZeneca’s Division of Cardiovascular and Metabolic Diseases. Dr. Okerson has a diverse medical and scientific background, with over 15 years of full-time clinical practice and leadership experience. For the past twenty years, he has exemplified a successful transition to industry, working as a Medical Director in various aspects of the pharmaceutical industry from clinical trial design to late phase clinical development and medical affairs for various well-known companies. In his current role, Dr. Okerson educates HCPs, works across specialties for internal collaborations, and strives to improve patient care.

Sponsored by AstraZeneca Pharmaceuticals, LP